QIPT · As filed with the SEC
Quipt Home Medical income statement, by fiscal year
The statement as Quipt Home Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF INCOME (LOSS) · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Sep 30, 2025 | FY2024 Year ended Sep 30, 2024 |
|---|---|---|
| Revenue | ||
| Rentals of medical equipment | 100,108,000 | 94,308,000 |
| Sales of medical equipment and supplies | 145,251,000 | 151,607,000 |
| Total revenues | 245,359,000 | 245,915,000 |
| Cost of inventory sold | 68,182,000 | 68,925,000 |
| Operating expenses | 125,457,000 | 122,542,000 |
| Right-of-use operating lease amortization and interest | 6,434,000 | 5,974,000 |
| Depreciation | 39,429,000 | 38,490,000 |
| Amortization of intangible assets | 6,053,000 | 6,091,000 |
| Stock-based compensation | 4,035,000 | 2,484,000 |
| Acquisition-related costs | 817,000 | 401,000 |
| Gain on disposals of property and equipment | (1,225,000) | (107,000) |
| Operating income (loss) | (3,823,000) | 1,115,000 |
| Interest expense | 6,744,000 | 7,168,000 |
| Interest income | (467,000) | (787,000) |
| Loss (gain) on foreign currency transactions | 367,000 | (43,000) |
| Share of loss in equity method investment | 324,000 | 309,000 |
| Change in fair value of derivative liability - interest rate swap | (452,000) | 1,122,000 |
| Loss before income taxes | (10,339,000) | (6,654,000) |
| Provision for income taxes | 241,000 | 109,000 |
| Net loss before noncontrolling interest | (10,580,000) | (6,763,000) |
| Net income attributable to noncontrolling interest | 121,000 | — |
| Net loss | (10,701,000) | (6,763,000) |
| Net income (loss) per share | ||
| Basic loss per share | (0.24) | (0.16) |
| Diluted loss per share | (0.24) | (0.16) |
| Weighted average number of common shares outstanding: | ||
| Basic (in shares) | 43,291 | 42,501 |
| Diluted (in shares) | 43,291 | 42,501 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.